New human insulin 'Ferulin' launched by BFBL  

ISLAMABAD: Ferozsons Laboratories’s subsidiary Pakistan’s BF Biosciences Limited (BFBL) has launched a new human insulin product under the brand name ‘Ferulin,’ to provide effective and affordable diabetes treatment to patients across Pakistan.
The company has announced this in a notice to the Pakistan Stock Exchange (PSX), saying, "We are pleased to inform you that BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has successfully launched human insulin under the brand name ‘Ferulin’." the company says.
Human insulin, a synthetic hormone identical to the insulin naturally produced by the pancreas, is crucial for regulating blood glucose levels, especially in individuals with diabetes.
It says the launch of Ferulin is a significant milestone for BFBL in its ongoing efforts to combat diabetes, expand its product portfolio, and enhance the availability of essential medicines in the market. 
BFBL expressed confidence that the introduction of Ferulin will drive growth for the subsidiary and bolster its mission to address unmet patient needs.
BFBL, a joint venture between Ferozsons Laboratories Limited and Argentina’s Bagó Group, specializes in importing, manufacturing, marketing, and distributing pharmaceutical products. 
The company is also preparing for an initial public offering (IPO) on the PSX, aiming to raise at least Rs1.375 billion ($4.94 million) by issuing 25 million shares at a floor price of Rs55 per share.
BFBL is recognized for contributing to the local production of hepatitis-related medications, including interferon injections. Additionally, in 2020, BFBL secured a non-exclusive license agreement with Gilead Sciences, Inc. to manufacture and sell Remdesivir, an antiviral drug for Covid-19 treatment, which contributed approximately Rs2 billion to its revenue during FY2021-FY2022.